CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $1M, lower than 95% of all stocks globally
- PositionOperating margin is -7765.9%, lower than 95% of its Biotechnology peers (median -24.1%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.80BUSDvs all stocks (USD)
Revenue (TTM)
1.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
-1.02xvs all stocks
52-Week Change
33.93%vs all stocks
Market Capitalization
1.80BUSDvs all stocks (USD)
Enterprise Value
1.41BUSDvs all stocks (USD)
Forward P/E
-5.78xvs Biotechnology peers
Price to Book (MRQ)
6.91xvs Biotechnology peers
Enterprise to Revenue
1.41Kxvs Biotechnology peers
Enterprise to EBITDA
-5.15xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-34.42%vs Biotechnology peers
Return on Equity (TTM)
-199.04%vs Biotechnology peers
Revenue (TTM)
1.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.0190USDUpdated Sep 29, 2026Gross Profit (TTM)
-212.47MUSDvs all stocks (USD)
EBITDA (TTM)
-273.87MUSDvs all stocks (USD)
Net Income (TTM)
-484.38MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-225.97MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-211.39MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
10.00MUSDFY2025 · Dec 31, 2025Operating Income
-211.38MUSDvs all stocks (USD)
Pre-tax Income
-377.82MUSDFY2025 · Dec 31, 2025Income Tax Expense
-79.00KUSDFY2025 · Dec 31, 2025Net Income
-377.74MUSDFY2025 · Dec 31, 2025EBIT
-370.49MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-198.76MUSDFY2025 · Dec 31, 2025Research & Development
168.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
53.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.15MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.33MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-377.74MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-182.41MUSDFY2025 · Dec 31, 2025Free Cash Flow
-182.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
110.64MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-377.74MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
56.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
26.35MUSDFY2025 · Dec 31, 2025Other Non-cash Items
179.87MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-10.04MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-902.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-18.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-35.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-417.75MUSDFY2025 · Dec 31, 2025Sale of Investments
200.89MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-216.89MUSDFY2025 · Dec 31, 2025Other Financing Charges
62.34MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
210.91MUSDFY2025 · Dec 31, 2025Shares Outstanding
63.33MSharesUpdated Sep 29, 2026Float Shares
45.02MSharesUpdated Sep 29, 2026Shares Short
11.87MSharesUpdated Sep 29, 2026Short Ratio
17.04daysvs all stocks
Short % of Shares Outstanding
26.74%vs all stocks
% Held by Insiders
19.75%vs all stocks
% Held by Institutions
100.88%vs all stocks
Total Cash (MRQ)
643.13MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
9.87USDUpdated Sep 29, 2026Total Debt (MRQ)
297.86MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
1.21xvs Biotechnology peers
Current Ratio (MRQ)
9.93xvs Biotechnology peers
Book Value per Share (MRQ)
3.90USDUpdated Sep 29, 2026Total Assets
383.64MUSDvs all stocks (USD)
Total Current Assets
351.17MUSDFY2025 · Dec 31, 2025Total Liabilities
141.50MUSDFY2025 · Dec 31, 2025Total Non-current Assets
32.47MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
78.85MUSDFY2025 · Dec 31, 2025Total Current Liabilities
62.65MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
110.64MUSDFY2025 · Dec 31, 2025Other Short-term Investments
232.55MUSDFY2025 · Dec 31, 2025Accounts Payable
7.11MUSDFY2025 · Dec 31, 2025Short-term Debt
1.11MUSDFY2025 · Dec 31, 2025Long-term Debt
211.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
78.64MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-765.13MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
242.14MUSDvs all stocks (USD)
52-Week Low
13.50USDUpdated Sep 29, 202652-Week High
44.60USDUpdated Sep 29, 202652-Week Change
33.93%vs all stocks
Beta
-1.02xvs all stocks
50-Day MA
31.60USDUpdated Sep 29, 2026200-Day MA
25.60USDUpdated Sep 29, 2026Avg 10-Day Volume
824.31KSharesUpdated Sep 29, 2026Avg 30-Day Volume
738.41KSharesUpdated Sep 29, 2026Diluted EPS (TTM)
-9.63USDUpdated Sep 29, 2026Other Income / Expense
-171.25MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -7765.9%, lower than 95% of its Biotechnology peers (median -24.1%)Significant
Operating margin: -77.66Industry median: -0.24Industry P5: -33.54Peers compared: 193
Return on equity is -199%, lower than 95% of its Biotechnology peers (median -23.6%)Significant
Return on equity: -1.99Industry median: -0.24Industry P5: -1.76Peers compared: 193
Financial Health
Altman Z-Score 2.56: grey zoneSignificant
Altman Z-Score: 2.56
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $1M, lower than 95% of all stocks globallySignificant
Revenue (USD): 1,000,000Global P5: 33,357,653.812
Levered free cash flow is -$211.39M, lower than 95% of all stocks globallySignificant
Levered free cash flow (USD): -211,391,632Global P5: -202,685,365.334
Market cap is $1.8B, above the global median of $1.18BNotable
Market cap (USD): 1,795,618,718Global Median: 1,180,223,658.953
Companies that share the same coordination system — how they create, deliver, or capture value.
Xeris Biopharma Holdings, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jafron Biomedical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Vir Biotechnology Inc.
Tier 1ProductionApproval-Gated PipelineRule
Wedge Industrial Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Tibet Rhodiola Pharmaceutical Holding Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Alivus Life Sciences Limited
Tier 1ProductionApproval-Gated PipelineRuleFlow